The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 La Jolla Pharmaceutical Company  (LJPC) Trade Now »     Rate LJPC  -  Discuss LJPC  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
This is a micro-cap stock and may be a target of manipulation. Always do your research!

SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate LJPC:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

LJPC: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

From the Blogosphere

After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
The After-Hours Movers lists the top gaining/declining stocks in after-hours trading:La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through...
By  Street Insider   (+0.33%  risk: moderate)  01/06/09 Comment


After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
The After-Hours Movers lists the top gaining/declining stocks in after-hours trading:La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through...
By  Street Insider   (+0.33%  risk: moderate)  01/06/09 Comment


After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
The After-Hours Movers lists the top gaining/declining stocks in after-hours trading:La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through...
By  Street Insider   (+0.33%  risk: moderate)  01/06/09 Comment


After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
The After-Hours Movers lists the top gaining/declining stocks in after-hours trading:La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through...
By  Street Insider   (+0.33%  risk: moderate)  01/06/09 Comment


After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million ...
By  Street Insider   (+0.33%  risk: moderate)  01/06/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
GLD streetTRACKS Gold
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
BIDU Baiducom Inc ADS
DRYS DryShips Inc.
AAPL Apple Computer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on LJPC

Visit streetinsider.com


Discussion Wall + Add  
amritadas   (+0.00%)
A FREE report on upcoming FDA decision for small ca.. - FDA decision date coming up this month for small cap company's Pain drug. If the FDA approves the drug, the peak sales could reach over 200% of the com...
+   0 replies

amritadas   (+0.00%)
Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...
+   0 replies


More Resources

Graphic_arrow1 About La Jolla Pharmaceutical Company - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch